Investment Strategy Overview - The report emphasizes two main investment themes for the chemical industry: anti-involution policies and domestic substitution, which are expected to drive recovery and growth in the sector [4][5][6] Anti-Involution and Cycle Recovery - The report suggests that the chemical industry is at a turning point, with anti-involution measures leading to a recovery in the cycle. Key areas include the peak of new capacity in organic silicon, the end of PTA capacity expansion, and a rebound in prices for certain chemicals due to supply chain disruptions [4][5] - The China Chemical Product Price Index (CCPI) has decreased significantly, dropping to 3865 points by November 30, 2025, down 16.37% from early 2024 and 10.71% from the beginning of 2025 [4][20] Domestic Substitution as a Growth Driver - Domestic substitution is highlighted as a key growth driver, with significant support from national policies for bio-based materials and advancements in technology leading to a more robust domestic supply chain [4][6] - The report identifies several companies positioned to benefit from these trends, including KaiSai Bio and RuiFeng New Materials, which are making strides in bio-based materials and lubricant additives, respectively [5][6] Market Dynamics and Price Recovery - The report notes that while the chemical market is experiencing a downturn, certain segments are expected to see price recovery due to improved supply-demand dynamics and reduced capacity expansion [4][22] - Specific chemical products have shown varied price movements, with some experiencing significant declines while others are stabilizing or recovering [22] Manufacturing Sector Recovery - The manufacturing sector is showing signs of recovery, which is anticipated to support the chemical industry. The report mentions that the real estate market is stabilizing, and automotive production has increased, indicating a potential uptick in demand for chemical products [25][33] Capital Expenditure Trends - Capital expenditure growth in the chemical industry is slowing, with a notable decline in new projects. The report indicates that the total construction in progress for the chemical sector was 327.57 billion yuan in Q3 2025, down 17.64% year-on-year [34][39] Inventory and Consumption Trends - High inventory levels in the chemical sector are being addressed as consumer demand begins to recover. The report suggests that the inventory-to-revenue ratio for the basic chemical industry was 0.62 in Q3 2025, indicating a slight increase from the previous year [41][42] Profitability and Financial Performance - The report highlights a recovery in profitability for the chemical industry, with gross margins and return on equity (ROE) showing improvement in Q3 2025 compared to previous periods [56][60] - Specific sub-sectors, such as agrochemicals and fluorochemicals, have demonstrated significant profit growth, with some exceeding 100% year-on-year increases [55][56]

内容概要：热塑性聚酰胺（PA），俗称尼龙，是一种综合性能优异、可通过多种改性技术灵活调控性 能的热塑性工程塑料，广泛应用于各工业领域。中国热塑性聚酰胺行业正处在规模扩张与结构升级并行 的关键阶段。从市场规模看，行业整体保持高速增长，其中聚酰胺类材料凭借其出色的机械性能与加工 适应性，在热塑性复合材料市场中占据主导地位，其市场规模持续扩大，市场核心地位不断巩固。聚焦 核心品类，PA6作为通用主力，已进入理性健康的增长周期，产能扩张与下游需求形成了良性互动，行 业运行效率提升，国际贸易结构发生根本性转变，从净进口转为竞争力强劲的净出口；而PA66产业则 在关键原料"卡脖子"问题取得突破后，进入产能快速释放期，目前面临阶段性供需结构再平衡的挑战， 未来发展的关键在于推进高端应用替代与提升出口竞争力。未来行业将聚焦高温、生物基等高端品类研 发与回收技术产业化，巩固原料自主化成果并推进产业链一体化，在深化传统应用领域的同时拓展新兴 场景，向高端化、自主化与多元化稳步迈进。 上市企业：万华化学（600309.SH）、神马股份（600810.SH）、金发科技（600143.SH）、鲁西化工 （000830.SZ）、宁德时代 ...

Core Viewpoint - Specialty nylon, as a high-performance polyamide material system beyond general nylon (PA6, PA66), is a key direction for the new materials industry towards high-end, functional, and green development. It overcomes the limitations of conventional nylon in heat resistance, water absorption, and transparency through molecular structure design and synthesis process innovation, leading to various subcategories widely used in advanced manufacturing fields such as automotive electrification, electronics, new energy equipment, and aerospace [1][2]. Group 1: Overview of Specialty Nylon - Specialty nylon refers to polyamide materials excluding general nylons (PA6 and PA66), including long-chain polyamides, high-temperature polyamides, transparent polyamides, and bio-based polyamides (PA56), with long-chain nylon and high-temperature nylon dominating the market [5][6]. - The global specialty nylon market is currently dominated by international giants such as Arkema, Evonik, and DuPont, with significant technological barriers in key monomers, polymerization processes, and high-end grades [1][10]. Group 2: Market Supply and Demand - The global production capacity of specialty nylon is approximately 600,000 tons per year, with major producers including Arkema, DuPont, DSM, and others. DSM uniquely masters the industrialization of hexamethylenediamine, producing PA4T, while other companies primarily focus on PA6T products [10][11]. - In China, domestic production of long-chain polyamides has gained a significant market share, with several companies planning to expand production capacity, expected to reach 150,000 tons in the next five years [14][13]. Group 3: Long-Chain Polyamides - Long-chain nylon typically refers to nylon materials with more than ten methylene groups in the molecular chain, offering high toughness and low water absorption, with applications in automotive, electronics, and military sectors [16][20]. - The global production capacity of long-chain polyamides is around 270,000 tons per year, with a projected market sales revenue of $2.846 billion in 2024, expected to reach $3.64 billion by 2031, reflecting a CAGR of 3.6% [21][23]. Group 4: High-Temperature Polyamides - High-temperature polyamides can operate at temperatures up to 150°C, with a global production capacity of approximately 335,000 tons per year. They are widely used in electronics, automotive, and mechanical manufacturing [26][32]. - The production of high-temperature nylon involves complex synthesis processes, with the two-step method of high-temperature high-pressure solution polymerization followed by solid-phase post-polymerization being the mainstream industrial process [28][31].

Core Insights - The chemical industry is entering a favorable phase driven by demand, value, and supply dynamics [5][6][7] - Global supply constraints and the exit of European capacities are expected to enhance the market environment for the chemical sector [7] Demand Drivers - Key opportunities identified in various sectors include: - Gas turbine upstream: companies like Zhenhua Co., Yingliu Co., Longda Co., and Wanze Co. [5] - Refrigerants and fluorinated liquids: companies such as Juhua Co., New Zhoubang, and Runhe Materials [5] - Energy storage supply chain: including Chuanheng Co., Xingfa Group, Yuntianhua, Batian Co., and others [5] - Semiconductor materials: companies like Yanggu Huatai, Wanrun Co., Dinglong Co., and others [5] Value Drivers - Potential for increased dividend yields in sectors such as: - Coal chemical: Hualu Hengsheng, Luxi Chemical, and Baofeng Energy [6] - Oil refining: Hengli Petrochemical, Satellite Chemical, and Sinopec [6] - Phosphate fertilizers: Yuntianhua, Yuntu Holdings, and others [6] Supply Drivers - Domestic anti-involution policies and the exit of European production capacities are expected to support the chemical industry: - PTA and polyester filament: companies like Xin Fengming and Tongkun Co. [7] - Tire manufacturing: including Sailun Tire, Zhongce Rubber, and others [7] Key Companies and Profit Forecasts - Selected companies with profit forecasts include: - Zhenhua Co. (Net profit forecast for 2025: 6.04 billion, PE: 21.8) [8] - Yingliu Co. (Net profit forecast for 2025: 4.08 billion, PE: 42.7) [8] - Longda Co. (Net profit forecast for 2025: 1.06 billion, PE: 34.9) [8] - Wanze Co. (Net profit forecast for 2025: 2.37 billion, PE: 32.9) [8] - Juhua Co. (Net profit forecast for 2025: 48.14 billion, PE: 24.4) [8] Industry Cycle Insights - The chemical industry is expected to enter a new cycle, with demand recovery and supply-side reforms driving growth [14][21] - The chemical price index has shown signs of recovery, indicating a potential upturn in the market [20][21]

浦江蜿蜒，润泽上海多个产业园区；浪涛汹涌，击打出创新的节拍；货轮远航，驶向广阔的国际市 场……"十五五"规划建议擘画出未来五年的战略蓝图，一批上海科创公司为国担当、勇为尖兵，瞄准创 新与国际化"双线突围"，谋篇布局高质量发展。 硬核创新是扎根本土的底气。上海完善的科创生态，为企业攻坚"卡脖子"技术提供了肥沃土壤。乘着上 海支持创新创业的东风，80后的大学生创业者谢应波带领泰坦科技，在科学服务行业闯出一条国产化之 路；从生物材料到生物制造，凯赛生物手握颠覆性创新技术，大胆挺进合成生物产业蓝海；面对"数据 危机"带来的挑战，英方软件接连翻越研发、市场与信任"三座山"，以硬实力打造数据"保险栓"；20年 精耕细作，从3G到6G，创远信科不断夯实通信测试技术底座，用"工业之尺"刻画着产业新高度。 开放布局是链接全球的桥梁。依托上海国际科创中心的优势，科创企业家不约而同将未来五年的发展目 光投向国际市场。凯赛生物董事长刘修才说，公司要成为世界生物制造产业的开拓者，并培养中国生物 制造的同路人。在泰坦科技的"征途墙"上，董事长谢应波为"十五五"之路贴上了一个新的关键词 ——"出海"。面对海外客户对中国基础软件的偏见，英方 ...

Core Insights - The article discusses the transformative potential of biomanufacturing, which utilizes microorganisms to create sustainable products, thereby reducing reliance on fossil fuels and minimizing environmental impact [1][2][4]. Group 1: Biomanufacturing Overview - Biomanufacturing is defined as a process where microorganisms convert renewable resources into valuable products, such as biodegradable plastics and high-performance materials [2][3]. - The shift from traditional petrochemical-based production to biomanufacturing is seen as essential for achieving a more sustainable industrial model [2][4]. Group 2: Economic Impact and Market Potential - The biomanufacturing industry in China is approaching a total scale of nearly 1 trillion yuan, driven by policy support and capital investment [6]. - Utilizing agricultural waste, such as crop straw, could potentially generate over 1 million tons of biodegradable plastic annually, creating a market worth hundreds of billions [5][6]. Group 3: Industry Development and Collaboration - Companies like Kasei Biotech are forming strategic partnerships to develop biobased materials, demonstrating a collaborative approach to building a competitive biomanufacturing ecosystem [7]. - The integration of biomanufacturing in various sectors, including healthcare and consumer products, is expanding, with companies innovating in areas like biodegradable medical materials and low-sugar food products [8]. Group 4: Challenges and Barriers - The biomanufacturing sector faces challenges in scaling up from laboratory to industrial production, particularly in optimizing microbial strains and production processes [9][10]. - Regulatory hurdles and slow approval processes for genetically engineered strains hinder the speed of innovation and market entry for new biomanufactured products [9][10].

Core Viewpoint - On November 25, 2023, a block trade of Kaisa Bio occurred with a volume of 1.1243 million shares, amounting to 43.2406 million yuan, at a price of 38.46 yuan, representing a discount of 20.85% compared to the closing price of the day [2] Trading Activity Summary - The block trade involved a total volume of 1.1243 million shares and a transaction amount of 43.2406 million yuan, with a transaction price of 38.46 yuan, reflecting a discount of 20.85% relative to the closing price of the day [2] - The buyer and seller for this transaction were both from Changcheng Securities Co., Ltd., Chongqing Xinnan Road Securities Business Department [2] Stock Performance Summary - Kaisa Bio's closing price on the same day was 48.59 yuan, which increased by 1.08%, with a turnover rate of 0.59% and a total transaction amount of 169 million yuan [2] - The stock experienced a net outflow of 369,100 yuan in main funds throughout the day, and over the past five days, the stock has cumulatively decreased by 2.17%, with a total net outflow of 27 million yuan [2] Margin Trading Summary - The latest margin financing balance for Kaisa Bio is 598 million yuan, which has increased by 42.0896 million yuan over the past five days, reflecting a growth rate of 7.57% [2] Company Background - Shanghai Kaisa Bio Technology Co., Ltd. was established on November 24, 2000, with a registered capital of 7.21289794 billion yuan [2]

证券日报网讯凯赛生物11月25日在互动平台回答投资者提问时表示，安徽禾纤作为公司全资子公司，定 位于系列生物基聚酰胺改性树脂的研发、生产和销售，下游应用方向包括汽车管路、乘用车内外饰、低 压电器、复合材料等场景领域，目前在设备安装调试阶段，尚未投产。 ...

（文章来源：证券日报） 证券日报网讯 11月21日晚间，凯赛生物发布公告称，公司全体董事一致同意选举臧慧卿女士为公司第 三届董事会副董事长。 ...

公司董事会于近日收到董事长、总裁 XIUCAI LIU（刘修才）先生递交的辞 去公司总裁职位的书面报告。XIUCAI LIU（刘修才）先生辞去总裁职务后，仍继 续担任董事长、董事会战略委员会召集人、董事会提名委员会成员以及公司首席 科学家的职务，将主要精力投入到公司战略规划、重大项目推动以及高端人力培 养等方面。 证券代码：688065 证券简称：凯赛生物 公告编号：2025-063 上海凯赛生物技术股份有限公司 关于高级管理人员变更及选举副董事长的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、高级管理人员离任情况 （一）提前离任的基本情况 特此公告。 上海凯赛生物技术股份有限公司 董事会 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 | 是否继续在上 市公司及其控 股子公司任职 | 具体职务 | 是否存在 未履行完 毕的公开 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 承诺 | | XIUCAI ...